Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
Business|Economy|Health|Political|US
FDA fires most negotiators for pharma user fee talks, sources say
The U.S.
Latest From Maggie Fick
Business|Economy|Europe|Health|Political|Science|Stock Markets|Technology|US
Trump health policy uncertainty sends biotech sector into deeper slump
Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling through a prolonged downturn
Business|Economy|Europe|Health|Political
European pharma companies warn Trump's tariffs could expedite shift to US
European pharma companies warned the European Commission president at a meeting on Tuesday that U.S. tariffs would expedite the industry's
Business|Economy|Europe|Political
EU Commission head discusses response to tariffs with auto, steel and pharma leaders
European Commission President Ursula von der Leyen held a call with metals industry representatives on Monday and was due to speak later to
Business|Health|Political|Science|US
Trump layoffs begin to erode FDA drug review system
The Trump administration's mass firings at the U.S.
Business|Economy|Finance|Health|Political|Stock Markets|US
Pharma stocks survive market rout on tariff exemption, but uncertainty continues
Drugmaker stocks gained a temporary reprieve on Thursday as U.S.
Business|Europe|Health
Novo Nordisk's head of commercial strategy steps down
Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish
Business|Europe|Finance|Health
Novo Holdings nearly doubles earnings as Wegovy swells coffers
Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment returns to a
Business|Economy|Health|Political|US
Pharma industry lobbies Trump for phased tariffs, sources say
Drugmakers are lobbying U.S.
Business|Europe|Finance|Health|Stock Markets
BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag
Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and
Business|Europe|Finance|Health|Stock Markets
Novo shares on track for biggest monthly fall since 2002, investor worries grow
Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify
Business|Economy|Europe|Health|Political|US
Trump tariff threats prompt some drugmakers to expedite shipments to US
Some drugmakers are taking the unusual step of sending more medicines by air to the U.S., two executives and two
Asia|Business|Economy|Health
AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-
Business|Europe|Political|US
Novartis scraps use of diverse panels for hires in US
Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told Reuters on Wednesday, citing
Business|Europe|Political|US
Swiss drugmakers Novartis and Roche ditch some diversity programmes on US concerns
Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse panels for U.S. hiring, the
Business|Economy|Europe|Health|Political|US
Big pharma fears best-selling drugs in crosshairs of US-EU tariff spat
Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff wars, hoping to avert price spikes on top-
